Werewolf Therapeutics, Inc.

Potenza Therapeutics, Inc.

Novartis Ag

Dana-farber-cancer Institute Inc.

Children's Medical Center Corporation

Trieza Therapeutics, Inc.

Daniel Hicklin

William Winston

Cynthia Seidel-Dugan

Heather R Brodkin

Vinay Bhaskar

Patrick A Baeuerle

Luke Evnin

Nels P Nielson

Jose Andres Salmeron Garcia

Gordon James Freeman

Maximiliano Vasquez

Walter A Blattler

Holger Wesche

Thomas Huber

Jennifer Marie Mataraza

Dale T Umetsu

Barbara Brannetti

Fangmin Xu

Catherine Anne Sabatos-Peyton

Tiancen Hu

Thomas Pietzonka

John A Taraszka

Rosemarie H DeKruyff

Alan S Harris

Jose-Andres Salmeron-Garcia

Philipp Steiner

Cynthia S Dugan

Jose Andres Salemeron-garcia

Kenneth Nelson Wills

Sonja Kleffel

Christopher James Nirschl

Shuoyen Jack Lin

Cynthia Seidel-dugan

Heather Brodkin

Patrick Baeuerle

The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin 12 polypeptides and methods of use thereof

The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.

Activatable cytokine polypeptides and methods of use thereof

The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g. a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.

The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable interleukin-2 polypeptides and methods of use thereof

Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Anti-TIGIT antigen-binding proteins and methods of uses thereof

Anti-TIGIT antigen-binding proteins and methods of use thereof

Provided herein are antibodies, or antigen binding fragments thereof, that selectively bind to NRP-1 and its isoforms and homologs, and compositions comprising the antibodies, or antigen binding fragments thereof. Also provided are methods of using the antibodies, or antigen binding fragments thereof, such as therapeutic and diagnostic methods.

Anti-neuropilin antigen-binding proteins and methods of use thereof

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Method of detecting TIM-3 using antibody molecules to TIM-3

Provided herein are antigen-binding proteins (ABPs) that selectively bind to GITR and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

Anti-GITR antigen-binding proteins and methods of use thereof

Antibody molecules to TIM-3 and uses thereof

Activatable interleukin 12 polypeptides

Activatable interleukin-2 polypeptides

Growing community of inventors

Montclair, NJ, United States of America

Daniel Hicklin